CN115867545A8 - 抗病毒素1,3-二氧代茚化合物 - Google Patents

抗病毒素1,3-二氧代茚化合物 Download PDF

Info

Publication number
CN115867545A8
CN115867545A8 CN202180029147.1A CN202180029147A CN115867545A8 CN 115867545 A8 CN115867545 A8 CN 115867545A8 CN 202180029147 A CN202180029147 A CN 202180029147A CN 115867545 A8 CN115867545 A8 CN 115867545A8
Authority
CN
China
Prior art keywords
compounds
dioxoindene
antiviral
salts
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029147.1A
Other languages
English (en)
Other versions
CN115867545A (zh
Inventor
J·内伊特斯
D·普恩
K·B·普菲斯特
郑永植
韩水逢
Y·R·玛尔帕尼
P·查克拉萨里
B·K·比斯瓦斯
金天生
申珍洙
金海洙
李钟娇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Novartis AG
Korea Research Institute of Chemical Technology KRICT
Original Assignee
Katholieke Universiteit Leuven
Novartis AG
Korea Research Institute of Chemical Technology KRICT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Novartis AG, Korea Research Institute of Chemical Technology KRICT filed Critical Katholieke Universiteit Leuven
Publication of CN115867545A publication Critical patent/CN115867545A/zh
Publication of CN115867545A8 publication Critical patent/CN115867545A8/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明提供了如本文所述的式(I)的化合物，以及药学上可接受的盐，含有此类化合物的药物组合物，以及使用这些化合物、盐和组合物治疗病毒感染的方法。
CN202180029147.1A 2020-04-20 2021-04-20 抗病毒素1,3-二氧代茚化合物 Pending CN115867545A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063012780P 2020-04-20 2020-04-20
US63/012,780 2020-04-20
PCT/EP2021/060271 WO2021214080A1 (en) 2020-04-20 2021-04-20 Antiviral 1,3-di-oxo-indene compounds

Publications (2)

Publication Number Publication Date
CN115867545A CN115867545A (zh) 2023-03-28
CN115867545A8 true CN115867545A8 (zh) 2023-09-05

Family

ID=75660016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029147.1A Pending CN115867545A (zh) 2020-04-20 2021-04-20 抗病毒素1,3-二氧代茚化合物

Country Status (9)

Country Link
US (1) US20210323947A1 (zh)
EP (1) EP4139301A1 (zh)
JP (1) JP2023521237A (zh)
KR (1) KR20230024886A (zh)
CN (1) CN115867545A (zh)
AU (2) AU2021260796A1 (zh)
CA (1) CA3176618A1 (zh)
TW (1) TW202200565A (zh)
WO (1) WO2021214080A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2838703C (en) * 2011-06-16 2017-12-19 Korea Research Institute Of Chemical Technology Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases

Also Published As

Publication number Publication date
US20210323947A1 (en) 2021-10-21
CN115867545A (zh) 2023-03-28
EP4139301A1 (en) 2023-03-01
WO2021214080A1 (en) 2021-10-28
JP2023521237A (ja) 2023-05-23
TW202200565A (zh) 2022-01-01
AU2024203286A1 (en) 2024-06-06
KR20230024886A (ko) 2023-02-21
CA3176618A1 (en) 2021-10-28
AU2021260796A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
WO2019139899A8 (en) Benzamide compounds
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
WO2016096174A8 (en) Cyclic dinucleotides for cytokine induction
WO2020160193A3 (en) Compounds and uses thereof
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
SG149067A1 (en) IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
MX2022007372A (es) Compuestos de heteroarilo sustituidos utiles como activadores de celulas t.
WO2008100447A3 (en) Nucleoside analogs for antiviral treatment
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX2022002897A (es) Profarmacos antivirales y formulaciones de los mismos.
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
CA2415010A1 (en) Propane-1,3-dione derivatives useful as gnrh receptor antagonist
MX2022007369A (es) Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
WO2008021038B1 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
JP2020097577A5 (zh)
SE0302192D0 (sv) Novel compounds
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
EP1928884A4 (en) 5,6-DIMETHYLTHIENO [2,3-DI] PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE FIGHT AGAINST VIRUSES
MX2020007521A (es) Inhibidores de pi4kiii.
MX2020011089A (es) Compuestos antiproliferacion y usos de los mismos.
IL276194B2 (en) Pharmaceutical compounds or preparations containing them for use in the treatment of pain
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MXPA04006041A (es) Antivirales de piridoquinoxalina.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Applicant|Address|Applicant

Correct: NOVARTIS AG|Basel, SUI|Catholic University of Leuven|Korea Chemical Research Institute

False: NOVARTIS AG|Basel, SUI|Catholic University of Leuven|Korean Institute of Chemistry

Number: 13-01

Page: The title page

Volume: 39

Correction item: Applicant|Address|Applicant

Correct: NOVARTIS AG|Basel, SUI|Catholic University of Leuven|Korea Chemical Research Institute

False: NOVARTIS AG|Basel, SUI|Catholic University of Leuven|Korean Institute of Chemistry

Number: 13-01

Volume: 39

CI02 Correction of invention patent application
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088484

Country of ref document: HK